Liquiritigenin can also mitigate the suppression of cisplatin-induced MB by enhancing the expression of NFE2L2 and SIRT3, which promotes PGC-1α and TFAM expression, thereby improving MB and providing protective effects against cisplatin-induced AKI.86 The gene discussed is TFAM; the disease is acute kidney injury.